Diabetes, Vol 48, Issue 4 870-880, Copyright © 1999 by American Diabetes Association

ARTICLES

Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial

VM Monnier, O Bautista, D Kenny, DR Sell, J Fogarty, W Dahms, PA Cleary, J Lachin and S Genuth
Institute of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA. vmm3@po.cwru.edu

The relationships between long-term intensive control of glycemia and indicators of skin collagen glycation (furosine), glycoxidation (pentosidine and N(epsilon)-[carboxymethyl]-lysine [CML]), and crosslinking (acid and pepsin solubility) were examined in 216 patients with type 1 diabetes from the primary prevention and secondary intervention cohorts of the Diabetes Control and Complications Trial. By comparison with conventional treatment, 5 years of intensive treatment was associated with 30-32% lower furosine, 9% lower pentosidine, 9-13% lower CML, 24% higher acid-soluble collagen, and 50% higher pepsin-soluble collagen. All of these differences were statistically significant in the subjects of the primary prevention cohort (P < 0.006-0.001) and also of the secondary intervention cohort (P < 0.015-0.001) with the exception of CML and acid-soluble collagen. Age- and duration-adjusted collagen variables were significantly associated with the HbA1c value nearest the biopsy and with cumulative prior HbA1c values. Multiple logistic regression analyses with six nonredundant collagen parameters as independent variables and various expressions of retinopathy, nephropathy, and neuropathy outcomes as dependent variables showed that the complications were significantly associated with the full set of collagen variables. Surprisingly, the percentage of total variance (R2) in complications explained by the collagen variables ranged from 19 to 36% with the intensive treatment and from 14 to 51% with conventional treatment. These associations generally remained significant even after adjustment for HbA1c, and, most unexpectedly, in conventionally treated subjects, glycated collagen was the parameter most consistently associated with diabetic complications. Continued monitoring of these subjects may determine whether glycation products in the skin, and especially the early Amadori product (furosine), have the potential to be predictors of the future risk of developing complications, and perhaps be even better predictors than glycated hemoglobin (HbA1c).
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Brignardello, C. Runzo, M. Aragno, M. G. Catalano, M. Cassader, P. C. Perin, and G. Boccuzzi Dehydroepiandrosterone Administration Counteracts Oxidative Imbalance and Advanced Glycation End Product Formation in Type 2 Diabetic Patients Diabetes Care, November 1, 2007; 30(11): 2922 - 2927. [Abstract] [Full Text] [PDF]

				J. M. Lachin, S. Genuth, D. M. Nathan, and B. N. Rutledge The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial Diabetes, July 1, 2007; 56(7): 1913 - 1921. [Abstract] [Full Text] [PDF]

				J. D. Maynard, M. Rohrscheib, J. F. Way, C. M. Nguyen, and M. N. Ediger Noninvasive Type 2 Diabetes Screening: Superior sensitivity to fasting plasma glucose and A1C Diabetes Care, May 1, 2007; 30(5): 1120 - 1124. [Abstract] [Full Text] [PDF]

				R. Meerwaldt, H. L. Lutgers, T. P. Links, R. Graaff, J. W. Baynes, R. O.B. Gans, and A. J. Smit Skin Autofluorescence Is a Strong Predictor of Cardiac Mortality in Diabetes Diabetes Care, January 1, 2007; 30(1): 107 - 112. [Abstract] [Full Text] [PDF]

				H. L. Lutgers, R. Graaff, T. P. Links, L. J. Ubink-Veltmaat, H. J. Bilo, R. O. Gans, and A. J. Smit Skin Autofluorescence as a Noninvasive Marker of Vascular Damage in Patients With Type 2 Diabetes Diabetes Care, December 1, 2006; 29(12): 2654 - 2659. [Abstract] [Full Text] [PDF]

				P. A. Cleary, T. J. Orchard, S. Genuth, N. D. Wong, R. Detrano, J.-Y. C. Backlund, B. Zinman, A. Jacobson, W. Sun, J. M. Lachin, et al. The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Diabetes, December 1, 2006; 55(12): 3556 - 3565. [Abstract] [Full Text] [PDF]

				The Diabetes Control and Complications Trial/Epide Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes N. Engl. J. Med., December 22, 2005; 353(25): 2643 - 2653. [Abstract] [Full Text] [PDF]

				R. Meerwaldt, J. W.L. Hartog, R. Graaff, R. J. Huisman, T. P. Links, N. C. den Hollander, S. R. Thorpe, J. W. Baynes, G. Navis, R. O.B. Gans, et al. Skin Autofluorescence, a Measure of Cumulative Metabolic Stress and Advanced Glycation End Products, Predicts Mortality in Hemodialysis Patients J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3687 - 3693. [Abstract] [Full Text] [PDF]

				S. Genuth, W. Sun, P. Cleary, D. R. Sell, W. Dahms, J. Malone, W. Sivitz, V. M. Monnier, and for the DCCT Skin Collagen Ancillary Study Group Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes Diabetes, November 1, 2005; 54(11): 3103 - 3111. [Abstract] [Full Text] [PDF]

				J. M. Forbes, S. R. Thorpe, V. Thallas-Bonke, J. Pete, M. C. Thomas, E. R. Deemer, S. Bassal, A. El-Osta, D. M. Long, S. Panagiotopoulos, et al. Modulation of Soluble Receptor for Advanced Glycation End Products by Angiotensin-Converting Enzyme-1 Inhibition in Diabetic Nephropathy J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2363 - 2372. [Abstract] [Full Text] [PDF]

				G. T. Mustata, M. Rosca, K. M. Biemel, O. Reihl, M. A. Smith, A. Viswanathan, C. Strauch, Y. Du, J. Tang, T. S. Kern, et al. Paradoxical Effects of Green Tea (Camellia Sinensis) and Antioxidant Vitamins in Diabetic Rats: Improved Retinopathy and Renal Mitochondrial Defects but Deterioration of Collagen Matrix Glycoxidation and Cross-Linking Diabetes, February 1, 2005; 54(2): 517 - 526. [Abstract] [Full Text] [PDF]

				M. E. Obrenovich and V. M. Monnier Apoptotic Killing of Fibroblasts by Matrix-Bound Advanced Glycation Endproducts Sci. Aging Knowl. Environ., January 26, 2005; 2005(4): pe3 - pe3. [Abstract] [Full Text]

				V. Thallas-Bonke, C. Lindschau, B. Rizkalla, L. A. Bach, G. Boner, M. Meier, H. Haller, M. E. Cooper, and J. M. Forbes Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C-{alpha}-Dependent Pathway Diabetes, November 1, 2004; 53(11): 2921 - 2930. [Abstract] [Full Text] [PDF]

				J. M. Forbes, L. T. L. Yee, V. Thallas, M. Lassila, R. Candido, K. A. Jandeleit-Dahm, M. C. Thomas, W. C. Burns, E. K. Deemer, S. R. Thorpe, et al. Advanced Glycation End Product Interventions Reduce Diabetes-Accelerated Atherosclerosis Diabetes, July 1, 2004; 53(7): 1813 - 1823. [Abstract] [Full Text] [PDF]

				M. Svensson, J. W. Eriksson, and G. Dahlquist Early Glycemic Control, Age at Onset, and Development of Microvascular Complications in Childhood-Onset Type 1 Diabetes: A population-based study in northern Sweden Diabetes Care, April 1, 2004; 27(4): 955 - 962. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Aspects of Blood Pressure, Lipid, and Glycemic Treatment Diabetes Care, January 1, 2004; 27(1): 264 - 269. [Full Text] [PDF]

				P. A. Voziyan, R. G. Khalifah, C. Thibaudeau, A. Yildiz, J. Jacob, A. S. Serianni, and B. G. Hudson Modification of Proteins In Vitro by Physiological Levels of Glucose: PYRIDOXAMINE INHIBITS CONVERSION OF AMADORI INTERMEDIATE TO ADVANCED GLYCATION END-PRODUCTS THROUGH BINDING OF REDOX METAL IONS J. Biol. Chem., November 21, 2003; 278(47): 46616 - 46624. [Abstract] [Full Text] [PDF]

				M. Peppa, H. Brem, P. Ehrlich, J.-G. Zhang, W. Cai, Z. Li, A. Croitoru, S. Thung, and H. Vlassara Adverse Effects of Dietary Glycotoxins on Wound Healing in Genetically Diabetic Mice Diabetes, November 1, 2003; 52(11): 2805 - 2813. [Abstract] [Full Text] [PDF]

				Writing Team for the Diabetes Control and Complica Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study JAMA, October 22, 2003; 290(16): 2159 - 2167. [Abstract] [Full Text] [PDF]

				D. R. Sell, M. A. Lane, M. E. Obrenovich, J. A. Mattison, A. Handy, D. K. Ingram, R. G. Cutler, G. S. Roth, and V. M. Monnier The Effect of Caloric Restriction on Glycation and Glycoxidation in Skin Collagen of Nonhuman Primates J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2003; 58(6): B508 - 516. [Abstract] [Full Text] [PDF]

				P. Odetti, C. Pesce, N. Traverso, S. Menini, E. P. Maineri, L. Cosso, S. Valentini, S. Patriarca, D. Cottalasso, U. M. Marinari, et al. Comparative Trial of N-Acetyl-Cysteine, Taurine, and Oxerutin on Skin and Kidney Damage in Long-Term Experimental Diabetes Diabetes, February 1, 2003; 52(2): 499 - 505. [Abstract] [Full Text] [PDF]

				E. Black, J. Vibe-Petersen, L. N. Jorgensen, S. M. Madsen, M. S. Agren, P. E. Holstein, H. Perrild, and F. Gottrup Decrease of Collagen Deposition in Wound Repair in Type 1 Diabetes Independent of Glycemic Control Arch Surg, January 1, 2003; 138(1): 34 - 40. [Abstract] [Full Text] [PDF]

				V. M. Monnier and M. E. Obrenovich Wake Up and Smell the Maillard Reaction Sci. Aging Knowl. Environ., December 18, 2002; 2002(50): pe21 - 21. [Abstract] [Full Text]

				S.V. McLennan, S.K.Y. Martell, and D.K. Yue Effects of Mesangium Glycation on Matrix Metalloproteinase Activities: Possible Role in Diabetic Nephropathy Diabetes, August 1, 2002; 51(8): 2612 - 2618. [Abstract] [Full Text] [PDF]

				The Writing Team for the Diabetes Control and Comp Effect of Intensive Therapy on the Microvascular Complications of Type 1 Diabetes Mellitus JAMA, May 15, 2002; 287(19): 2563 - 2569. [Abstract] [Full Text] [PDF]

				P. A. Voziyan, T. O. Metz, J. W. Baynes, and B. G. Hudson A Post-Amadori Inhibitor Pyridoxamine Also Inhibits Chemical Modification of Proteins by Scavenging Carbonyl Intermediates of Carbohydrate and Lipid Degradation J. Biol. Chem., January 25, 2002; 277(5): 3397 - 3403. [Abstract] [Full Text] [PDF]

				M. T. Goova, J. Li, T. Kislinger, W. Qu, Y. Lu, L. G. Bucciarelli, S. Nowygrod, B. M. Wolf, X. Caliste, S. F. Yan, et al. Blockade of Receptor for Advanced Glycation End-Products Restores Effective Wound Healing in Diabetic Mice Am. J. Pathol., August 1, 2001; 159(2): 513 - 525. [Abstract] [Full Text]

				I. G. OBROSOVA, C. VAN HUYSEN, L. FATHALLAH, X. CAO, M. J. STEVENS, and D. A. GREENE Evaluation of {alpha}1-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense FASEB J, August 1, 2000; 14(11): 1548 - 1558. [Abstract] [Full Text]

				V. Scivittaro, M. B. Ganz, and M. F. Weiss AGEs induce oxidative stress and activate protein kinase C-beta II in neonatal mesangial cells Am J Physiol Renal Physiol, April 1, 2000; 278(4): F676 - F683. [Abstract] [Full Text] [PDF]

				The Diabetes Control and Complications Trial/Epide Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy N. Engl. J. Med., February 10, 2000; 342(6): 381 - 389. [Abstract] [Full Text] [PDF]

				D. R. SELL, N. R. KLEINMAN, and V. M. MONNIER Longitudinal determination of skin collagen glycation and glycoxidation rates predicts early death in C57BL/6NNIA mice FASEB J, January 1, 2000; 14(1): 145 - 156. [Abstract] [Full Text]